- Report
- September 2023
- 110 Pages
Global
From €5752EUR$5,950USD£4,944GBP
- Report
- February 2024
- 175 Pages
Global
From €4834EUR$5,000USD£4,155GBP
- Report
- November 2023
- 150 Pages
Global
From €4689EUR$4,850USD£4,030GBP
- Report
- December 2018
- 161 Pages
Global
From €1329EUR$1,375USD£1,142GBP
€2658EUR$2,750USD£2,285GBP
- Report
- April 2023
- 394 Pages
Global
From €7250EUR$7,500USD£6,232GBP
- Report
- April 2023
- 200 Pages
United States
From €3625EUR$3,750USD£3,116GBP
- Report
- January 2021
- 298 Pages
Global
From €6719EUR$6,950USD£5,775GBP
- Report
- July 2020
- 200 Pages
Global
From €6719EUR$6,950USD£5,775GBP
- Report
- April 2024
- 50 Pages
Global
From €2562EUR$2,650USD£2,202GBP
Lomustine is a chemotherapy drug used to treat brain cancer. It is a nitrosourea, a type of alkylating agent, and works by interfering with the growth of cancer cells. It is used to treat a variety of brain tumors, including glioblastoma, anaplastic astrocytoma, and medulloblastoma. It is also used to treat other types of cancer, such as Hodgkin's lymphoma and non-Hodgkin's lymphoma.
Lomustine is available in both oral and intravenous forms. It is usually given in combination with other chemotherapy drugs, such as temozolomide or carboplatin. The drug is generally well tolerated, but can cause side effects such as nausea, vomiting, and hair loss.
The market for lomustine is highly competitive, with several companies offering the drug. Some of the major players in the market include Bristol-Myers Squibb, Merck, Pfizer, and Novartis. Other companies, such as Teva Pharmaceuticals and Mylan, also offer generic versions of the drug. Show Less Read more